Contineum Therapeutics, INC

Contineum Therapeutics reported Q2 2026 financial results, highlighting progress in its PROPEL-IPF trial and affirming its cash runway through mid-2029.

Contineum Therapeutics, Inc. has updated its corporate presentation on July 13, 2026, detailing business and strategic updates, including progress on its lead drug candidates PIPE-791 and PIPE-307.

Contineum Therapeutics stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.

Contineum Therapeutics reported Q1 2026 financial results, highlighting positive topline data from a chronic pain trial and affirming key clinical development milestones for its lead drug candidates.

Contineum Therapeutics announced positive topline results from its Phase 1b trial of PIPE-791, demonstrating safety and efficacy signals in chronic pain patients.

Contineum Therapeutics increased its at-the-market equity offering to $100 million, reported fourth-quarter 2025 financial results, and provided updates on its clinical pipeline, including the initiation of a Phase 2 IPF trial.

Contineum Therapeutics reports reduced operating expenses and increased cash reserves in Q2 2026, while advancing clinical trials for its lead drug candidates.

Contineum Therapeutics reports reduced R&D expenses and a net loss of $14.5 million for Q1 2026, with cash reserves projected to last over 12 months.

Contineum Therapeutics reported increased net losses in Q3 2025 and for the nine months ended September 30, 2025, while advancing its lead drug candidates PIPE-791 and PIPE-307 with key clinical trial milestones expected.

Contineum Therapeutics reports increased R&D expenses and net loss in Q2 2025, driven by active clinical trial progression for its neuroscience, inflammation, and immunology drug candidates.

Contineum Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and research and development activities.

Contineum Therapeutics reports a net loss of $10.3 million for the third quarter of 2024, with ongoing clinical trials and research and development activities.

Contineum Therapeutics, Inc. reported a net loss of $59.978 million for 2025, initiated a Phase 2 trial for PIPE-791 in IPF, and saw its partnered PIPE-307 fail its primary efficacy endpoints in RRMS.

Contineum Therapeutics files its 10-K report for fiscal year 2024, detailing financial results and providing updates on its clinical development programs, including PIPE-791 and PIPE-307.

Carmine N. Stengone, CEO and President and a Director of Contineum Therapeutics, Inc., sold 2,500 shares of common stock on August 3, 2026 for $16.01 per share.

Contineum Therapeutics reports insider transactions involving Class A Common Stock and stock options by Chief Scientific Officer Daniel S. Lorrain.

Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., reported the sale of 2,500 shares of Class A Common Stock through a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics reports insider transactions by Chief Scientific Officer Daniel S. Lorrain, involving stock option exercises and sales under a 10b5-1 plan.

Contineum Therapeutics' CMO & Head of Development, Tim Watkins, sold 10,833 shares of Class A Common Stock for approximately $16.02 per share, as part of a pre-arranged 10b5-1 trading plan.

Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., reported transactions involving Class A Common Stock and stock options on June 30, 2026, executed under a Rule 10b5-1 trading plan.

Contineum Therapeutics, Inc. has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026.

Contineum Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Contineum Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 26, 2025, featuring director elections and ratification of the company's independent accounting firm.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, is seeking to raise approximately $150 million through an initial public offering to advance its pipeline of therapies for neuroscience, inflammation, and immunology indications.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to further its development of oral small molecule therapies for neuroscience, inflammation, and immunology indications.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 931,709 shares, representing 2.8% of Contineum Therapeutics, Inc.'s Class A Common Stock.

RA Capital Management and its affiliates report a 4% beneficial ownership stake in Contineum Therapeutics, Inc. as of March 31, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 2,417,723 shares, representing 7.4% of Contineum Therapeutics, Inc.'s Class A Common Stock.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in Contineum Therapeutics, Inc. via a Schedule 13G filing.

Janus Henderson Group plc has reported a 7.9% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.

Balyasny Asset Management and its affiliates have reported a 7.6% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.